Business context and reporting period
4D Molecular Therapeutics, Inc. filed this Form 10-K for the fiscal year ended December 31, 2021. It is a clinical-stage gene therapy company developing targeted AAV-vector therapies using its Therapeutic Vector Evolution platform. It had no approved products and generated no product sales; reported revenue came from collaborations and licenses.
The company reported four candidates in Phase 1/2 trials—4D-125, 4D-150, 4D-110 and 4D-310—and an FDA-cleared IND for 4D-710. The filing’s descriptions of 4D-710’s trial status are inconsistent: one section says the trial was enrolling, while another says first dosing was expected in the first half of 2022.
Financial and operating performance
| Metric (USD millions, except per-share data) | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $18.0 | $13.6 | +$4.4; +33% |
| Research and development expense | $61.4 | $53.0 | +$8.3; +16% |
| General and administrative expense | $28.0 | $17.2 | +$10.8; +62% |
| Total operating expenses | $89.4 | $70.3 | +$19.1; +27% |
| Net loss | $(71.3) | $(56.7) | Loss increased $14.6 |
| Basic and diluted net loss per share | $(2.57) | $(8.82) | — |
| Net cash used in operating activities | $(69.1) | $(50.9) | Cash use increased $18.2 |
Revenue was primarily collaboration and license revenue, not product revenue. Roche contributed $17.2 million, about 95% of 2021 revenue. The filing reports no meaningful product margin; operating margins are not informative for this pre-commercial company. Stock-based compensation expense was $13.8 million, up from $5.0 million.
Liquidity, funding and obligations
At December 31, 2021, cash and cash equivalents were $153.0 million and marketable securities were $162.4 million, totaling $315.4 million. Current assets were $256.3 million and current liabilities were $16.3 million. The filing reported no borrowings or interest-bearing debt; operating lease liabilities totaled $16.4 million, including $1.2 million current. Undiscounted future minimum lease payments were $22.5 million.
Net cash used in investing activities was $172.7 million, mainly reflecting $168.6 million of marketable-security purchases and $9.1 million of property and equipment purchases. Financing provided $118.1 million, including $114.3 million net proceeds from stock offerings. The November 2021 follow-on offering generated $111.1 million net. Management stated existing cash, equivalents and marketable securities were expected to fund planned operations for at least one year from the financial-statement issuance date; additional funding will be required, and availability on acceptable terms is not assured.
Material changes, outlook and risks
- Revenue rose, but operating expenses grew faster in absolute terms and the net loss widened. R&D payroll and personnel costs increased; G&A increases included public-company costs, recruiting and stock compensation.
- Roche terminated its collaboration effective September 16, 2021. Rights to 4D-110 data and collaboration-generated intellectual property reverted to 4DMT, but Roche milestones and royalties ceased. A termination-related accounting adjustment contributed to recognition of previously deferred revenue, including an $11.1 million increase related to work performed in prior periods.
- The company reported recurring losses, an accumulated deficit of $207.0 million, and no expected product revenue in the foreseeable future. It plans to continue investing in clinical development, research and manufacturing capacity; no specific financial guidance was provided.
- Interim clinical evidence remains limited. 4D-310 showed increased AGA activity in three reported patients, but one patient experienced a serious adverse event involving transient atypical hemolytic uremic syndrome and hospitalization. In the 4D-110 trial, pigment dispersion was reported in three patients at the higher dose and classified as serious adverse events; two were asymptomatic and one reported mild glare. 4D-125 had no dose-limiting toxicities or serious adverse events in the reported eight patients as of the stated data cutoff.
- Key risks include clinical failure or adverse events, regulatory uncertainty for gene therapies, manufacturing and supply constraints, trial delays including COVID-19 impacts, dependence on external funding, competition, intellectual-property and licensing risks, and uncertain future coverage and reimbursement. The company reported no material legal proceedings. Management said disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness under the company’s emerging-growth-company exemption.
Important facts for investors to verify
- Current cash runway and quarterly cash use, including how much is held in cash versus marketable securities and the timing of planned manufacturing investments.
- Updated trial enrollment, follow-up and safety data—especially the 4D-310 aHUS event and 4D-110 pigment-dispersion cases—and reconciliation of the filing’s 4D-710 trial-status descriptions.
- How the loss of Roche collaboration revenue affects future revenue, 4D-110 development, and any potential royalty obligation if the company advances without a new Phase 1/2a trial.
- Progress toward scalable manufacturing, clinical supply availability and funding needs; also assess dilution from future equity financing.
- Whether collaboration revenue remains concentrated, and whether clinical findings and regulatory milestones support the company’s stated development plans.